Univariate and multivariate analyses defined no statistical difference of reconstruction rate between patients with HER2-overexpressing and triple negative breast cancer (chi-square test: P = 0.063; logistic regression: HER-overexpressing vs triple negative OR 1.106, 95% CI 0.995–1.230). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.